# Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

> **NCT01209325** · PHASE2 · COMPLETED · sponsor: **AIDS Malignancy Consortium** · enrollment: 149 (actual)

## Conditions studied

- Anal Cancer
- Nonneoplastic Condition
- Penile Cancer
- Precancerous Condition

## Interventions

- **BIOLOGICAL:** quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01209325
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-28
- **Primary completion:** 2017-12-12
- **Final completion:** 2017-12-12
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2020-08-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209325, "Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01209325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*